Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.

Surgical oncology - 1 Jun 2020

Lowder Cinthya Y, Dhir Teena, Goetz Austin B, Thomsett Henry L, Bender Joseph, Tatarian Talar, Madhavan Subha, Petricoin Emanuel F, Blais Edik, Lavu Harish, Winter Jordan M, Posey James, Brody Jonathan R, Pishvaian Michael J, Yeo Charles J

Abstract excerpt

BACKGROUND: There is a lack of precision medicine in pancreatic ductal adenocarcinoma (PDA) and related cancers, and outcomes for patients with this diagnosis remain poor despite decades of research investigating this disease. Therefore, it is necessary to explore novel therapeutic options for these patients who may benefit from personalized therapies. OBJECTIVE: Molecular profiling of hepatopancreaticobiliary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Feasibility Studies

Share to Molecular Targeted Therapy

Share to Pancreatectomy

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Proteomics

Share to Registries

Source

Open in PubMed Open full text

Identifiers

PMID: 32561076
DOI: 10.1016/j.suronc.2020.02.003
PMCID: PMC7498307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.PMID 32561076Read ↗

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelSemantic proximity Read ↗

Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017.Semantic proximity Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.Semantic proximity Read ↗

Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)Semantic proximity Read ↗

Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable MutationsSemantic proximity Read ↗

Pancreatic biomarkers: could they be the answer?Semantic proximity Read ↗

Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future PerspectivesSemantic proximity Read ↗

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.Semantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.